Hematological Malignancies

Phase II Pivotal Study of BV Safety (AEs in ≥20% of pts)

All Grades (%)

Grade 3 (%)

Grade 4 (%)

Adverse event

Peripheral sensory neuropathy

47 46 42 37 36 29 22 22 21

9 2 0 0 1 2 0 0

0 0 0 0 0 0 6 0 0

Fatigue Nausea

Upper respiratory tract infection

Diarrhoea Pyrexia Neutropenia Vomiting

14

Cough

BV – brentuximab vedotin; AEs – adverse events; pts – patients

Adapted from Chen R et al. ASH 2012, abstract A3689